1996 diagnostic and classification criteria for the antiphospholipid/cofactors syndrome: A 'mission impossible'?

Lupus

Volumn 5, Issue 5, 1996, Pages 354-363

  Piette, J C ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Anticardiolipin antibodies; Antiphospholipid syndrome; Lupus anticoagulant; Systemic lupus erythematosus; Thrombosis; 2 glycoprotein I

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT;

ANTIPHOSPHOLIPID SYNDROME; CONFERENCE PAPER; DISEASE CLASSIFICATION; PRIORITY JOURNAL; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

EID: 0029832053     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/096120339600500504     Document Type: Conference Paper

References (93)

1. Harris EN, Baguley E, Asherson RA, Hughes GRV. Clinical and serological features of the 'antiphospholipid syndrome'. Br J Rheumatol 1987; 26 (suppl 2): 19.
2. Hughes GRV. The anticardiolipin syndrome. Clin Exp Rheumatol 1985; 3: 285-286.
3. Harris EN, Exner T, Hughes GR, Asherson RA (Eds). Phospholipid-Binding Antibodies. CRC Press: Boca Raton, 1991, pp 435.
4. Asherson RA, Cervera R, Piette JC, Shoenfeld Y (Eds). The Antiphospholipid Syndrome. CRC Press: Boca Raton, 1996, pp 339.
5. Asherson RA. A 'primary' antiphosphohpid syndrome?. J Rheumatol 1988; 15: 1742-1746.
6. Alarcon-Segovia D, Sanchez-Guerrero J. Primary antiphospholipid syndrome. J Rheumatol 1989; 16: 482-488.
7. Asherson RA et al. The 'primary' antiphospholipid syndrome: major clinical and serological features. Medicine 1989; 68: 366-374.
8. Harris EN. A reassessment of the antiphospholipid syndrome. J Rheumatol 1990; 17: 733-735.
9. Petri M. Epidemiology of the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette JC, Shoenfeld Y (Eds). The Antiphospholipid Syndrome. CRC Press: Boca Raton, 1996, pp 13-28.
10. Harris EN, Pierangeli S, Birch D. Anticardiolipin wet workshop report - Fifth international symposium on antiphospholipid antibodies. Am J Clin Pathol 1994; 101: 616-624.
11. Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: Results of the Second International Workshop for identification of lupus anticoagulants. Thromb Haemost 1995; 74: 1597-1603.
12. Alarcon-Segovia D et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine 1989; 68: 353-365.
13. Alarcon-Segovia D et al. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum 1992; 21: 275-286.
14. Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome. J Rheumatol 1992; 19: 1778-1781.
15. Piette JC, Wechsler B, Bletry O, Godeau P. Quels critères pour le diagnostic du syndrome des antiphospholipides?. Rev Med Interne 1993; 14: 799-803.
16. Jennette JC et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-192.
17. Lie JT. Nomenclature and classification of vasculitis: plus Ça change, plus c'est la même chose. Arthritis Rheum 1994; 37: 181-186.
18. Asherson RA, Piette JC, Cervera R. 'Primary', 'Secondary', 'Catastrophic', and other variants of the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette JC, Shoenfeld Y (Eds). The Antiphospholipid Syndrome. CRC Press: Boca Raton, 1996, pp 249-258.
19. Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
20. Piette JC, Wechsler B, Frances C, Godeau P. Systemic lupus erythematosus and the antiphospholipid syndrome: reflections about the relevance of ARA criteria. J Rkeumatol 1992; 19: 1835-1837.
21. Piette JC, Wechsler B, Frances C, Papo T, Godeau P. Exclusion criteria for primary antiphospholipid syndrome. J Rheumatol 1993; 20: 1802-1804.
22. Lie JT. Pathology of the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette JC, Shoenfeld Y (Eds). The Antiphospholipid Syndrome. CRC Press: Boca Raton, 1996, pp 89-104.
23. Andrews PA, Frampton G, Cameron JS. Antiphospholipid syndrome and systemic lupus erythematosus. Lancet 1993; 342: 988-989.
24. Mujic F et al. Primary arttiphospholipid syndrome evolving into systemic lupus erythematosus. J Rheumatol 1995; 22: 1589-1592.
25. Papo T et al. T lymphocytes subsets in primary antiphospholipid syndrome. J Rheumatol 1994; 21: 2242-2245.
26. Papo T et al Expression of soluble Fas mRNA in mononuclear cells correlates with apoptosis levels in vitro in SLE, but not in primary antiphospholipid syndrome. Lupus 1996; 5:5 (abstract).
27. Piette JC et al. Nonlesional sun-exposed Lupus Band test is negative in primary antiphospholipid syndrome. Lupus 1995; 4 (suppl 2): 24 (abstract).
28. Wilson WA et al. Familial anticardiolipin antibodies and C4 deficiency genotypes that coexist with MHC DQB1 risk factors. J Rheumatol 1995; 22: 227-235.
29. Biousse V, Piette JC. Genetic aspects of the primary antiphospholipid syndrome. Nouv Rev Fr Hematol 1995; 37 (suppl II): S65-S67.
30. Bentolila S et al. High frequency of C4 'null' alleles in primary antiphospholipid syndrome. Ann Med Interne 1996; 147: 115-116.
31. Ruffatti A et al. Antiphospholipid antibody syndrome associated with ovarian cancer, A new paraneoplastic syndrome?. J Rheumatol 1994; 21: 2162-2163.
32. Bessis D et al. Trousseau's syndrome with nonbacterial thrombotic endocarditis: Pathogenic role of antiphospholipid syndrome. Am J Med 1995; 98: 511-513.
33. Piette JC. What is going to happen tomorrow regarding the antiphospholipid syndrome?. Ann Med Interne 1995; 146: 555-558.
34. Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303-308.
35. Vianna IL et al. Comparison of the primary and secondary antiphospholipid syndrome: a european multicenter study of 114 patients. Am J Med 1994; 96: 3-9.
36. Levine SR et al. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neural 1995; 38: 119-124.
37. Khamashta MA et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-997.
38. Ravelli A, Caporali R, Montecucco C, Martini A. The antiphospholipid syndrome in childhood. J Rheumatol 1996; 23: 1121-1122.
39. Hage ML et al. Fetal renal vein thrombosis, hydrops fetalis, and maternal lupus anticoagulant. A case report. Prenat Diagn 1994; 14: 873-877.
40. Antiphospholipid Antibodies in Stroke Study Group. Anticardiolipin antibodies arc an independent risk factor for first ischemic stroke. Neurology 1993; 43: 2069-2073.
41. Manoussakis MN et al. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol 1987; 69: 557-565.
42. Sebastiani GD, Galeazzi M Immunogenetics of the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette JC, Shoenfeld Y (Eds). The Antiphospholipid Syndrome. CRC Press: Boca Raton, 1996, pp 49-58.
43. Kingsmore SF et al. Clinical and genetic features of 12 families with an inherited primary antiphospholipid antibody syndrome. Arthritis Rheum 1994; 37 (suppl): S296 (abstract).
44. Crassard I et al. Familial primary antiphospholipid syndrome. Lupus 1996; 5:5 (abstract).
45. Asherson RA et al. Myocardial infarction and antiphospholipid antibodies in SLE and related disorders. Q J Med 1989; 73: 1103-1115.
46. Kincaid-Smith P, Fairley KP, Kloss M. Lupus anticoagulant associated with renal thrombotic rnicroangiopathy and pregnancy-related renal failure. Q J Med 1988; 69: 795-815.
47. Alegre VA, Gastineau DA, Winkelman RK. Skin lesions associated with circulating lupus anticoagulant. Br J Dermatol 1989; 120: 419-429.
48. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992; 19: 508-512.
49. Frances C et al. Multiple subungual splinter haemorrhages in the antiphospholipid syndrome: a report of five cases and review of the literature. Lupus 1994; 3: 121-128.
50. Bick RL, Baker WF. Antiphospholipid and thrombotic syndromes. Semin Thromb Uemost 1994; 20: 3-15.
51. Cervera R et al. High prevalence of significant heart valve lesions in patients with the 'primary' antiphospholipid syndrome. Lupus 1991; 1: 43-47.
52. Frances C, Bletry O, Piette JC. Dermatologic manifestations in the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette JC, Shoenfeld Y (Eds). The Antiphospholipid Syndrome. CRC Press: Boca Raton, 1996, pp 201-211.
53. Frances C et al. Sneddon's syndrome with or without antiphospholipid antibodies: a comparative study. Lupus 1996; 5:5 (abstract).
54. Asherson RA, Piette JC. The catastrophic antiphospholipid syndrome: 1996. Acute multi-organ failure associated with antiphospholipid antibodies: a review of 31 patients. Lupus 1996; 5:5.
55. Alarcon-Segovia D, Cabral AR. The antiphospholipid/cofactors syndromes. J Rheumatol 1996; 23: 1319-1322.
56. Kandiah DA, Krilis SA. Immunology and methods of detection of antiphospholipid antibodies. In: Asherson RA, Cervera R, Piette JC, Shoenfeld Y (Eds). The Antiphospholipid Syndrome. CRC Press: Boca Raton, 1996, 29-48.
57. 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus 1992; 1: 75-81.
58. 2 Glycoproteia-1 (apolipoprotein-H). J Clin Invest 1992; 90: 1105-1109.
59. Costing JD et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?. Blood 1993; 81: 2618-2625.
60. Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other antiphospholipid autoantibodies. Blood 1994; 84: 2854-2867.
61. 2-Glycoprotein I is potentiated by a distinct subgroup of anti-cardiolipin antibodies. Thromb Haemost 1992; 68: 297-300.
62. Sugi T, McIntyre JA. Auoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood 1995; 86: 3083-3089.
63. 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992; 93: 181-186.
64. 2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995; 22: 1899-1906.
65. 2-glycoprotein 1 and anti-prothrombin antibodies and their correlations with venous and arterial thrombosis. Ann Med Interne 1996; 147 (suppl I): 42-43.
66. 2-glycoprotein-I in patients with primary antiphospholipid syndrome. J Rheumatol 1995; 22: 1894-1898.
67. Boffa MC, Piette JC. Antiphospholipid antibodies: Paris-1995 recommendations. Nouv Rev Fr Hematol 1995; 37 (suppl II): S113-S116.
68. 2 glycoprotein I in Sneddon's syndrome. Dermatology 1993; 186: 273.
69. Vaarala O et al. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost 1996; 75: 456-459.
70. Cabral AR, Cabiedes J, Alarcon-Segovia D. Hemolytic anemia related to an IgM autoantibody to phosphatidylcholine that binds in vitro to stored and to bromelain-treated human erythrocytes. J Autoimmunity 1990; 3: 773-787.
71. Karmochkine M et al. Antiphosphatidylethanolamine antibody as the sole antiphospholipid antibody in systemic lupus erythematosus with thrombosis. Clin Exp Rheum 1992; 10: 603-605.
72. Berard M, Chanlome R, Marcelli A, Boffa MC. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. Association with thrombosis and vascular cutaneous diseases. J Rheumatol 1996; 23: 1369-1374.
73. Laroche P et al. Advantage of using both arnonic and zwitterionic antigens for the detection of antiphospholipid antibodies. Am J Clin Path 1996; (in press).
74. Fabris F et al. Specific antiplatelet autoantibodies in patients with antiphospholipid antibodies and thrombocytopenia. Eur J Haematol 1994; 53: 232-236.
75. Escalante A, Brey RL, Mitchell BD Jr, Dreiner U. Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus. Am J Med 1995; 98: 559-565.
76. Pierangeli SS et al. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost 1995; 74: 1361-1367.
77. Harris EN et al. Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med 1986; 146: 2153-2156.
78. Loizou S et al. Association of quantitative anticardiolipin antibody levels with fetal loss and time of loss in systemic lupus erythematosus. Q J Med 1988; 168: 525-531.
79. Peacock NW, Levine SP. The lupus anticoagulant-hypoprothrombinemia syndrome - Case report. Am J Med Sci 1994; 307: 346-349.
80. Piette JC, Cacoub P, Wechsler B Renal manifestations of the antiphospholipid syndrome. Sem Arthritis Rheum 1994; 23: 357-366.
81. Brunet P et al. Antiphospholipids in hemodialysis patients: Relation- ship between lupus anticoagulant and thrombosis. Kidney Int 1995; 48: 794-800.
82. Quintarelli C et al. Prevalence of lupus anticoagulant in patients with cirrhosis: Relationship with beta-2-glycoprotein I plasma levels. J Hepatol 1994; 21: 1086-1091.
83. Zuckerman E et al. Increased thromboembolic incidence in anticardiolipin-positive patients with malignancy. Br J Cancer 1995; 72: 447-451.
84. Loizou SA, Walport MJ, Davies KA. The antiphospholipid syndrome in infectious diseases. In: Asherson RA, Cervera R, Piette JC, Shoenfeld Y (Eds). The Antiphospholipid Syndrome. CRC Press: Boca Raton, 1996, pp 267-284.
85. Kerleau JM et al. Prevalence and evolution of anticardiolipin antibodies in giant cell arteritis during corticosteroid therapy. A prospective study of 20 consecutive cases. Br J Rhematol 1994; 33: 648-650.
86. 2 glycoprotein 1 antibodies: detection and association with thrombosis. Br J Haematol 1995; 89: 397-402.
87. 2-glycoprotein-I assay for discrimination between anticardiolipin antibodies associated with infection and increased risk of thrombosis. Brit J Haematol 1995; 91: 471-473.
88. 2-glycoprotein I on binding to phospholipid. J Rheumatol 1994; 21: 94-99.
89. Becker JC, Winkler B, Klingelt S, Brocker EB. Antiphospholipid syndrome associated with imnumotherapy for patients with melanoma. Cancer 1994; 73: 1621-1624
90. Oshiro BT et al. Antiphospholipid antibodies and fetal death. Obstet Gynecol 1996; 87: 489-493.
91. 2 glycoprotein I antibodies in the antiphospholipid syndrome. J Rheumatol 1994; 21: 1678-1683.
92. Meyer O et al. Antiphospholipid antibodies: a disease marker in 25 patients with antinuclear antibody negative systemic lupus erythematosus (SLE). Comparison with a group of 91 patients with antinuclear antibody positive SLE. J Rheumatol 1987; 14: 502-506.
93. Davies KA, Athanassiou P, Loizou SA. Thrombocytopenia and other haematological abnormalities in the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette JC, Shoenfeld Y (Eds). The Antiphospholipid Syndrome. CRC Press: Boca Raton, 1996, pp 219-234.